ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 794-801

  Sumitomo, Makoto ^a   Asano, Tomohiko ^a   Asakuma, Junichi ^a   Asano, Takako ^a   Horiguchi, Akio ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; PACLITAXEL; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 0842268375     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0948-03     Document Type: Article

References (34)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
2. Sokoloff, M. H., deKernion, J. B., Figlin, R. A., and Belldegrun, A. Current management of renal cell carcinoma. CA Cancer J. Clin., 46: 284-302, 1996.
3. Rosenberg, S. A. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J. Clin., 49: 70-73, 65, 1999.
4. Uhlman, D. L., Nguyen, P., Manivel, J. C., Zhang, G., Hagen, K., Fraley, E., Aeppli, D., and Niehans, G. A. Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer Res., 1: 913-920, 1995.
5. Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., and Tweardy, D. J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. (Bethesda), 90: 824-832, 1998.
6. Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Holscher, A. H., and Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res., 7: 1850-1855, 2001.
7. Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G., and Defilippi, P. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J., 17: 6622-6632, 1998.
8. Walker, F., Kato, A., Gonez, L. J., Hibbs, M. L., Pouliot, N., Levitzki, A., and Burgess, A. W. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol. Cell. Biol., 18: 7192-7204, 1998.
9. MacKeigan, J. P., Collins, T. S., and Ting, J. P. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem., 275: 38953-38956, 2000.
10. McDaid, H. M., and Horwitz, S. B. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol. Pharmacol., 60: 290-301, 2001.
11. Boldt, S., Weidle, U. H., and Kolch, W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis (Lond.), 23: 1831-1838, 2002.
12. Benhar, M., Engelberg, D., and Levitzki, A. Cisplatin-induced activation of the EGF receptor. Oncogene, 21: 8723-8731, 2002.
13. Ranson, M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist, 7 (Suppl. 4): 16-24, 2002.
14. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
15. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
16. Asakuma, J., Sumitomo, M., Asano, T., and Hayakawa, M. Selective Akt inactivation and tumor necrosis factor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res., 63: 1365-1370, 2003.
17. Sumitomo, M., Shen, R., Walburg, M., Dai, J., Geng, Y., Navarro, D., Boileau, G., Papandreou, C. N., Giancotti, F. G., Knudsen, B., and Nanus, D. M. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J. Clin. Investig., 106: 1399-1407, 2000.
18. Sumitomo, M., Ohba, M., Asakuma, J., Asano, T., Kuroki, T., and Hayakawa, M. Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J. Clin. Investig., 109: 827-836, 2002.
19. Horiguchi, A., Oya, M., Shimada, T., Uchida, A., Marumo, K., and Murai, M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J. Urol., 168: 762-765, 2002.
20. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.
21. Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res., 61: 7184-7188, 2001.
22. Anido, J., Matar, P., Albanell, J., Guzman, M., Rojo, F., Arribas, J., Averbuch, S., and Baselga, J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res., 9: 1274-1283, 2003.
23. Solomon, B., Hagekyriakou, J., Trivett, M. K., Stacker, S. A., McArthur, G. A., and Cullinane, C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int. J. Radiat. Oncol. Biol. Phys., 55: 713-723, 2003.
24. Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., and Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 62: 5749-5754, 2002.
25. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61: 3986-3997, 2001.
26. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
27. Magne, N., Fischel, J. L., Tiffon, C., Formento, P., Dubreuil, A., Renee, N., Formento, J. L., Francoual, M., Ciccolini, J., Etienne, M. C., and Milano, G. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br. J. Cancer, 89: 585-592, 2003.
28. Hu, Y., Bally, M., Dragowska, W. H., and Mayer, L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol. Cancer Ther., 2: 641-649, 2003.
29. Moch, H., Sauter, G., Buchholz, N., Gasser, T. C., Bubendorf, L., Waldman, F. M., and Mihatsch, M. J. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum. Pathol., 28: 1255-1259, 1997.
30. Lichtner, R. B., Menrad, A., Sommer, A., Klar, U., and Schneider, M. R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res., 61: 5790-5795, 2001.
31. Bianco, C., Tortora, G., Bianco, R., Caputo, R., Veneziani, B. M., Damiano, V., Troiani, T., Fontanini, G., Raben, D., Pepe, S., Bianco, A. R., and Ciardiello, F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res., 8: 3250-3258, 2002.
32. PMDEC Review of gefitinib (in Japanese). May 9, 2002. (http://www.pharmasys.gr.jp/shinyaku/g0207/06/67022700_21400AMY00188_250_l.pdf, accessed May 13, 2003).
33. Okano, J., and Rustgi, A. K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J. Biol. Chem., 276: 19555-19564, 2001.
34. Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M., Harper, M. E., Barrow, D., Wakeling, A. E., and Nicholson, R. I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 144: 1032-1044, 2003.